Business context and reporting period
This filing is Aquinox Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2014—not a Neurogene Inc. filing. Aquinox was a clinical-stage pharmaceutical company developing AQX-1125, a SHIP1 activator, for inflammatory diseases. It was conducting Phase 2 trials in COPD (FLAGSHIP) and bladder pain syndrome/interstitial cystitis (LEADERSHIP). The company reported no revenue.
Financial results and position
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $4.55M | $1.25M | $6.43M | $1.82M |
| General and administrative | $1.08M | $0.37M | $1.82M | $0.79M |
| Net loss | $5.42M | $0.81M | $9.65M | $1.82M |
| Operating cash used | $2.81M | $1.44M | $6.61M | $2.34M |
At June 30, cash and cash equivalents were $17.9M, short-term investments $18.0M, and long-term investments $16.5M—about $52.4M combined. Working capital was $33.5M. Total liabilities were $2.9M; the bank loan was repaid in March 2014, leaving no reported loan balance at quarter-end. No profit or operating margin is meaningful because the company had no revenue and incurred losses. Accumulated deficit was $75.0M.
Material changes versus the prior comparable period
- Q2 operating expenses rose to $5.63M from $1.62M, mainly reflecting the two active Phase 2 trials and increased public-company costs. Six-month expenses rose to $8.25M from $2.61M.
- Q2 net loss increased to $5.42M from $0.81M; six-month net loss increased to $9.65M from $1.82M. Comparisons are affected by the preferred-stock conversion, IPO and associated accounting items.
- March 2014 IPO generated $47.3M net proceeds. The company also converted preferred stock to common stock and repaid its $2.6M bank loan. Six-month financing cash flow was positive $45.3M, while Q2 financing cash flow was negative $0.4M, primarily due to remaining IPO costs.
- Investing activities used $31.8M in the first six months, mainly to purchase liquid securities; Q2 cash declined $35.0M, largely reflecting investment purchases.
Outlook, commentary and risks
- Management expected significant operating losses and rising R&D spending as clinical trials progressed. It stated existing capital resources were expected to fund operations for at least 12 months, while anticipating substantial future financing needs; additional financing might be unavailable or dilutive.
- FLAGSHIP was expanded to Australia and had added sites in the United States and New Zealand. LEADERSHIP expanded to U.S. sites after FDA acceptance of its IND. No trial results or financial guidance were provided.
- Key risks include clinical efficacy and safety uncertainty, the unvalidated SHIP1 target, regulatory and enrollment delays, reliance on third-party research organizations and manufacturers, and the need for additional capital. The filing notes mild gastrointestinal effects in prior AQX-1125 trials and animal toxicology findings; COPD exacerbations requiring hospitalization were reported as expected serious events in FLAGSHIP.
- A $3M milestone payment to Biolipox would be due upon commencement of a Phase 3 AQX-1125 trial; timing and likelihood were uncertain. The company reported no material legal proceedings and no off-balance-sheet arrangements.
- Management said disclosure controls were effective at a reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter. The filing also disclosed significant deficiencies identified during the audit of earlier-period financial statements.
Important facts for investors to verify
- Confirm the filing identity: the supplied filing is Aquinox Pharmaceuticals, Inc. (ticker AQXP), not Neurogene Inc.
- Track Phase 2 trial progress, enrollment, endpoints, safety updates and whether FDA will accept the COPD endpoint strategy for later-stage trials.
- Assess cash runway against the reported $6.6M six-month operating cash use and management’s expectation of future financing.
- Review the impact of the IPO, preferred-stock conversion and investment purchases on cash, share count and period-to-period comparability; 10.7M common shares were outstanding at June 30.
- Monitor the $3M Biolipox Phase 3 milestone, the post-IPO share overhang described in the filing, and remediation of previously identified internal-control deficiencies.